Literature DB >> 10604943

Anti-inflammatory activity of macrolide antibiotics.

A Ianaro1, A Ialenti, P Maffia, L Sautebin, L Rombolà, R Carnuccio, T Iuvone, F D'Acquisto, M Di Rosa.   

Abstract

The effect of four macrolide antibiotics (roxithromycin, clarithromycin, erythromycin, and azithromycin) on the generation of some mediators and cytokines involved in the inflammatory process has been studied both in vivo and in vitro. Rat carrageenin pleurisy was used as a model of acute inflammation, and the macrolides were administered (10, 20, and 40 mg/kg p.o.) 1 h before the carrageenin challenge. Exudate volume and leukocyte accumulation were both dose-dependently reduced by roxithromycin, clarithromycin and erythromycin in either normal or adrenalectomized animals. Furthermore, in normal rats, prostaglandin (PG)E(2), nitrate plus nitrite, and tumor necrosis factor-alpha levels in pleural exudate were significantly reduced by these macrolides. Roxithromycin appeared more effective than erythromycin and clarithromycin, whereas azithromycin only slightly affected the inflammatory reaction. None of the macrolides were able to modify leukotriene B(4) exudate levels. In vitro experiments have shown that the four macrolides (5-80 microM) reduced in a concentration-dependent manner the production of 6-keto-PGF(1alpha), NO(2)(-), tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6 by lipopolysaccharide-stimulated J774 macrophages. In J774 cells, the inhibition of 6-keto-PGF(1alpha) and NO(2)(-) production by roxithromycin and erythromycin was not dependent on direct inhibition of cyclooxygenase-2 and inducible nitric oxide synthase activity because it appears to be related to the inhibition of cyclooxygenase-2 and inducible nitric oxide synthase protein expression. In conclusion, the present study shows that macrolide antibiotics have anti-inflammatory activity, which likely depends on their ability to prevent the production of proinflammatory mediators and cytokines, and suggest that these agents, particularly roxithromycin, can exert therapeutic effects independently of their antibacterial activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10604943

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  81 in total

1.  Tilmicosin modulates the innate immune response and preserves casein production in bovine mammary alveolar cells during Staphylococcus aureus infection.

Authors:  Ismael Martínez-Cortés; Naray A Acevedo-Domínguez; Roxana Olguin-Alor; Arimelek Cortés-Hernández; Violeta Álvarez-Jiménez; Marcia Campillo-Navarro; Héctor S Sumano-López; Lilia Gutiérrez-Olvera; Daniel Martínez-Gómez; José L Maravillas-Montero; Juan J Loor; Eduardo A García-Zepeda; Gloria Soldevila
Journal:  J Anim Sci       Date:  2019-02-01       Impact factor: 3.159

2.  Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for ureaplasma colonization and bronchopulmonary dysplasia.

Authors:  Hazem E Hassan; Ahmed A Othman; Natalie D Eddington; Lynn Duffy; Li Xiao; Ken B Waites; David A Kaufman; Karen D Fairchild; Michael L Terrin; Rose M Viscardi
Journal:  J Clin Pharmacol       Date:  2010-11-23       Impact factor: 3.126

3.  Clarithromycin in the Treatment of Legionella pneumophila Pneumonia Associated with Multiorgan Failure in a Previously Healthy Patient.

Authors:  L Gallelli; V Gioffrè; G Vero; A Gallelli; F Roccia; S Naty; G Pelaia; A Capano; A Loiacono; G De Sarro; R Maselli
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

4.  Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.

Authors:  Thomas P Lodise; Andrea Kwa; Leon Cosler; Reetu Gupta; Raymond P Smith
Journal:  Antimicrob Agents Chemother       Date:  2007-08-20       Impact factor: 5.191

Review 5.  Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review.

Authors:  Donald M Arnold; Ashley Bernotas; Ishac Nazi; Roberto Stasi; Masataka Kuwana; Yang Liu; John G Kelton; Mark A Crowther
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

6.  A ceramide analog inhibits cPLA(2) activity and consequent PGE(2) formation in LPS-stimulated macrophages.

Authors:  Meir Goldsmith; Ala Daka; Nadia F Lamour; Roi Mashiach; Yifat Glucksam; Michael M Meijler; Charles E Chalfant; Tsaffrir Zor
Journal:  Immunol Lett       Date:  2010-10-30       Impact factor: 3.685

7.  Spontaneous onset of complex regional pain syndrome Type I in a woman infected with Bartonella koehlerae.

Authors:  Cristina Pérez Vera; Ricardo G Maggi; Christopher W Woods; Patricia E Mascarelli; Edward B Breitschwerdt
Journal:  Med Microbiol Immunol       Date:  2013-12-10       Impact factor: 3.402

8.  Impact of different antimycotics on cytokine levels in an in vitro aspergillosis model in human whole blood.

Authors:  Zoe Oesterreicher; Sabine Eberl; Markus Zeitlinger
Journal:  Infection       Date:  2019-08-01       Impact factor: 3.553

9.  Long term platelet responses to Helicobacter pylori eradication in Canadian patients with immune thrombocytopenic purpura.

Authors:  Shannon C Jackson; Paul Beck; Andre G Buret; Pamela M O'Connor; Jonathan Meddings; Graham Pineo; Man-Chiu Poon
Journal:  Int J Hematol       Date:  2008-08-01       Impact factor: 2.490

10.  Telithromycin treatment of chronic Chlamydia pneumoniae infection in C57BL/6J mice.

Authors:  Liisa Törmäkangas; Hannu Alakärppä; Denise Bem David; Maija Leinonen; Pekka Saikku
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.